Policymakers across the world are regularly required to make crucial decisions about resource allocation and prioritize interventions – medicine A or medicine B, subsidize heart surgery or expand the immunization program. This process is required to be transparent, accountable a

Beijing Children’s Hospital, Capital Medical University, National Centre for Children’s Health of China are committed to advancing skills in conducting comprehensive clinical evaluations of medicines. This commitment is evident through a variety of initiatives, including workshops, training, and aca

t is an uncomfortable question that, in today’s world, is often asked by expectant mothers who had more than one male partner at the time they became pregnant. Who is the father?With more than half of births to women under 30 now out of wedlock, it is a question that may arise more often.Now blood t

Balancing the right to know and the privacy of the patent system: a case study of oncology medicines in Thailand. Inthira Yamabhai; Richard D. Smith Abstract: This study aims to illustrate the processes to determine medicine patent status in developing countries by using oncology medicine in T

(Reuters) – AstraZeneca is to conduct a new global clinical trial of key new heart drug Brilinta involving 11,500 patients with peripheral artery disease, Britain’s second biggest drugmaker said on Tuesday.Peripheral artery disease affects around 27 million people in Europe and North America, with s

Abstract Background and Objectives The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m

Abstract Background and Objectives The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m

The study suggests that the price of patented medicine in Thailand should be controlled based on equity pricing and outcome pricing. Equity pricing can be estimated from the international reference price and outcome pricing can be evaluated from therapeutic referencing or the pharmacoeconomic price. Moreover, in a case study of 7 medicines granted

(Reuters) – Republican governors bent on rejecting the healthcare law’s expanded insurance coverage for millions of low-income Americans may see their gambit backfire if their party fails to sweep the November elections.Five governors have vowed to opt out of the Medicaid expansion for low-income pe

Highlights Economic evidence (cost-effectiveness information) can be used to inform policy-making process in supporting the movement towards universal health coverage. Published literature has focused on methods to set a cost-effectiveness threshold (CET) which can be used to guide the cost-eff